Table of Contents
| << Previous Issue | Sep 2012 (Vol: 2012, Issue: 9) | Next Issue >> |
- Section: Distribution & Marketing
-
Pfizer Signs Long-Term Generics Collaboration with Mylan in Japan
- Section: Joint Venture
-
AstraZeneca Forms Joint Venture with Wuxi AppTec to Accelerate Biologics Development in China
- Section: Licensing
-
Allergan Strengthens its Ophthalmology Pipeline with US$1.5 B Alliance with Molecular Partners
-
Genmab Signs US$1.1 B Daratumumab Licence Agreement with Janssen Biotech
-
Merck Serono Licenses Global Rights to Symphogen’s Sym004 Cancer Antibody Mixture
-
Pfizer Out-Licenses Clinical-Stage Cancer Antibody to VLST
-
Baxter Expands its Oncology Pipeline by Licensing European Rights to Onconova Therapeutics’ Rigosertib
- Section: Mergers & Acquisitions
-
Hospira Boosts Antibiotic Business with Acquisition of Orchid’s API Facilities
-
Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout
-
Sunovion Strengthens its Respiratory Portfolio by Acquiring Elevation Pharmaceuticals
-
Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option
- Section: Research & Development
-
Silence Therapeutics Collaborates with MiReven to Evaluate Delivery of miR-7 Mimetic
-
Sanofi Collaborates with Oncodesign to Develop Inhibitors of Challenging Kinase Targets
-
SFJ Pharmaceuticals to Conduct Phase III Trial of Pfizer’s Dacomitinib in First-Line Advanced NSCLC
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS